15-Aug-2020 | Market Research Store
Cannabis has shown to be effective in treating chronic pain arising in the sickle cell disease patients. The cannabis has been medically approved as a potential and safe drug. The researchers from the University of California have published their novel study in the JAMA Network Open. The vaporized form of cannabis is found to be generally safe. Furthermore, the previous studies have shown the sickle cell patients to experience severe pain such that painkillers cannot lower pain. However, the current study proves opioids to have the power to mitigate pain.
Speaking of cannabis, the public health crisis related to opioids is still a complicated process. The researchers are working toward offering a better picture of cannabis benefit in treating chronic pain. Opioids are being pioneered as the solution to lower chronic or acute pain occurring in case of the sickle cell disease. Meanwhile, the increasing number of deaths associated with opioid overdose is the major reason behind the medical professionals’ hesitation in prescribing cannabis. But, the pain alleviation in sickle cell disease has encouraged many patients to resort to cannabis. Additionally, the study on the effects of different forms of cannabis in treating chronic pain is in process. At present, the vaporized cannabis has been found to be safer as even the lower concentration of it is able to reach the body’s circulation.
The research on cannabis use in reducing pain still requires some evidence to back the theory. While cannabis is legalized only in a few countries there is requirement of fool-proof evidence for further use of opioids as a treatment for chronic pain in sickle cell patients.
Market Research Store has published a report on the global medical cannabis market. This report elaborately explains the factors surrounding the market dynamics and future market scope. Additionally, the report on medicinal cannabis also offers all the details whether qualitative or quantitative.
https://www.marketresearchstore.com/report/global-medical-cannabis-market-report-2019-434230